arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Neal Ready

1 paper · 2015–2015

2015: 1
2015peak 1 in 20152015

Frequent co-authors

Papers

showing 1–1 of 1 RSS

Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?

Jeffrey Clarke, Xiaofei Wang, Neal Ready

Statistics and Probability · PubMed · · cited 19× · DOI ↗ · more like this ·

Surrogate endpoints for clinical trials in oncology offer an alternative metric for measuring clinical benefit, allowing for shorter trial duration, smaller patient cohorts, and single arm design. The correlation of surrogate endpoints with overall survival (OS) in therapeutic studies is a central consideration to their validity. The Food and Drug Administration (FDA) recently published an analysis of fourteen clinical trials in advanced non-small cell lung cancer (NSCLC), and discovered a strong association between response rate and progression free survival. Furthermore, a correlation between response rate and OS is demonstrated when analyzing the experimental treatment arm separately, minimizing bias from patient crossover. We also highlight multiple, important considerations when using response as an endpoint in clinical trials involving NSCLC patients.